Japan’s key reimbursement policy panel has launched discussions on the FY2027 off-year drug price revision, with members voicing no objections to carrying out the revision itself. The upcoming debate will center on two key issues: the scope of target products…
To read the full story
Related Article
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
REGULATORY
- Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
August 18, 2026
- PMDA Urges Quality-Driven Biosimilar Development as CES Waivers Take Hold
August 18, 2026
- Japan Calls for APOE Testing before Leqembi, Kisunla Treatment
August 18, 2026
- Label Revised for DMD Drug Viltepso Based on PIII Miss
August 18, 2026
- Trazenta Draws 8 Generic Entrants as Japan Clears New DPP-4 Copies
August 17, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





